Compare Ascendis Pharma A/S (ASND) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs SYSCO Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while SYSCO Corporation trades at $84.35 (market cap $40.09B). The key difference: SYSCO Corporation is far larger — about 2.3× Ascendis Pharma A/S's market cap, and SYSCO Corporation pays a 2.62% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SYY | |
|---|---|---|
Market Cap | $17.74B | $40.09B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $91.16 |
52-Week Low | $163.32 | $69.30 |
Enterprise Value | $18.11B | $53.57B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SYY trades at $83.83, up 2.19% today, near the consensus price target of $83.67. The stock shows bullish technical signals with strong moving averages and support at $81. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed slightly. Revenue grew to $81.37B in 2025, with net income of $1.83B. The company maintains a dividend with the next payment scheduled for July 2026.
Outlook remains positive with 60% analyst buy ratings and a high target of $86. Risks include margin pressure from rising costs and competitive threats. The transformative Restaurant Depot acquisition could drive long-term growth, but investors should monitor execution and macroeconomic impacts on food distribution demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
